The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Feridex I.V. (generic name ferumoxides injectable solution) has
been approved as a contrast agent for magnetic resonance imaging
(MRI) of liver lesions. Feridex I.V. is the first organ-specific
MRI contrast agent to file with the FDA. Through the liver's
natural function, the agent is taken up by macrophages found only
in healthy liver cells but not in most tumors.
Feridex I.V. is marketed in the United States by Berlex
Laboratories. If you have questions regarding Feridex I.V. please
contact Berlex Laboratories, Inc. - Department of Epidemiology and
Medical Affairs at (800) 888-2407.For product information call
Feridex I.V. is marketed in western Europe by Guerbet
S.A. under the tradename Endorem.
Feridex I.V. is marketed in Japan under the tradename
Feridex by Eiken Chemical Co., Ltd, in association with Tanabe
Feridex I.V. is marketed in Argentina by Temis-Lostaló,
in South Korea byTaeJoon Pharmaceuticals, in Israel by Discotrade
and in China by Pharmagenesis, Inc.